Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease.
about
N-methyl D-aspartate (NMDA) receptor antagonists and memantine treatment for Alzheimer's disease, vascular dementia and Parkinson's diseaseSex differences in Parkinson's diseaseActivin A protects midbrain neurons in the 6-hydroxydopamine mouse model of Parkinson's diseaseProgressive Axonal Degeneration of Nigrostriatal Dopaminergic Neurons in Calcium-Independent Phospholipase A2β Knockout MiceDopamine transporter binding is unaffected by L-DOPA administration in normal and MPTP-treated monkeysBehavioural profiles in captive-bred cynomolgus macaques: towards monkey models of mental disorders?Targeting β-arrestin2 in the treatment of L-DOPA-induced dyskinesia in Parkinson's disease.The contribution of alpha synuclein to neuronal survival and function - Implications for Parkinson's diseaseThe nigrostriatal dopamine system of aging GFRalpha-1 heterozygous mice: neurochemistry, morphology and behaviorPSD-95 expression controls L-DOPA dyskinesia through dopamine D1 receptor traffickingNeuroanatomical study of the A11 diencephalospinal pathway in the non-human primateStriatal overexpression of DeltaJunD resets L-DOPA-induced dyskinesia in a primate model of Parkinson disease.Lack of additive role of ageing in nigrostriatal neurodegeneration triggered by α-synuclein overexpression.Distinct changes in cAMP and extracellular signal-regulated protein kinase signalling in L-DOPA-induced dyskinesia.Normalization and expression changes in predefined sets of proteins using 2D gel electrophoresis: a proteomic study of L-DOPA induced dyskinesia in an animal model of Parkinson's disease using DIGEMotor deficits and altered striatal gene expression in aphakia (ak) mice.Striatal proteomic analysis suggests that first L-dopa dose equates to chronic exposure.Aging reveals a role for nigral tyrosine hydroxylase ser31 phosphorylation in locomotor activity generation.Phasic dopamine release in appetitive behaviors and drug addiction.Hippocampal proliferation is increased in presymptomatic Parkinson's disease and due to microglia.Lentiviral overexpression of GRK6 alleviates L-dopa-induced dyskinesia in experimental Parkinson's disease.Basal Ganglia circuits underlying the pathophysiology of levodopa-induced dyskinesia.No differential regulation of dopamine transporter (DAT) and vesicular monoamine transporter 2 (VMAT2) binding in a primate model of Parkinson disease.Neurodegeneration in an animal model of Parkinson's disease is exacerbated by a high-fat diet.Dopamine transporter loss in 6-OHDA Parkinson's model is unmet by parallel reduction in dopamine uptake.Striatal and extrastriatal dopamine transporter levels relate to cognition in Lewy body diseases: an (11)C altropane positron emission tomography study.Electro-acupuncture stimulation improves spontaneous locomotor hyperactivity in MPTP intoxicated micePathophysiology of parkinsonism.Noradrenaline and Parkinson's disease.The involvement of neuroinflammation and kynurenine pathway in Parkinson's disease.Metabotropic glutamate receptor 5 antagonist protects dopaminergic and noradrenergic neurons from degeneration in MPTP-treated monkeys.Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease.Genetic deficiency of the mitochondrial protein PGAM5 causes a Parkinson's-like movement disorder.Pre-synaptic dopaminergic compensation after moderate nigrostriatal damage in non-human primates.Modeling Parkinson's disease in primates: The MPTP modelExtrastriatal D2-like receptors modulate basal ganglia pathways in normal and Parkinsonian monkeysPeripheral vs. Central Sex Steroid Hormones in Experimental Parkinson's Disease.Prefrontal Markers and Cognitive Performance Are Dissociated during Progressive Dopamine Lesion.Low nigrostriatal reserve for motor parkinsonism in nonhuman primates.Activin A Inhibits MPTP and LPS-Induced Increases in Inflammatory Cell Populations and Loss of Dopamine Neurons in the Mouse Midbrain In Vivo.
P2860
Q26825619-EBACDBEB-9457-461E-96C8-149AD728AA34Q27025107-BC138C90-2A58-45F6-9CC2-1FD74D6F7A21Q27309140-38B23ED4-8CAC-4747-AC7B-7996055CAA16Q27313281-179C5A14-1579-42CC-8A72-C85139513D91Q27316473-C048C909-C1E2-4CA0-87DC-EAAD6D67DC41Q27323164-D8411C0A-A232-48EF-9A58-5DD8001E4BBAQ27324174-035FAD24-71EE-4618-AECB-FB982E225B76Q28068464-1089C08A-FE0E-45F1-A6F8-F82AAD4F6FF0Q28510989-0E6F8BFA-052E-4BC4-A4E8-AEB9CC5DB1EDQ28582674-6BCDC7A1-9166-48D0-8CCC-24247322B621Q28748883-660F1A11-A6F8-4427-A8B0-1648EB50A9EEQ30493275-61795186-68CB-4719-B234-1FD1066D4E21Q30658867-6CCE56D9-B977-4D5C-A91E-AF8AB8BB0363Q30988635-5A6A8F23-1B10-4AA6-821E-E6147F282AB3Q33261647-F6F304B5-6409-4070-93E6-E87FBE172056Q33303267-3CF4D5AA-ADFB-4529-AC68-90F2566BC724Q33319566-B1E9EDA8-5982-46A8-A3A1-7FAD14E9D118Q33520922-C71905BA-BF97-4484-B308-D958E6271E1EQ33880993-863455EC-7B99-461E-BD8F-954E9569BB63Q34100703-D0DDBD55-6E85-4284-BCD2-0E859992D4A7Q34105586-5F186639-8DE2-42AF-B66C-5E4F8D6FD760Q34165820-18C32E40-C235-4683-8A4D-01AFBB98ABACQ34168229-117698DF-DC8D-4684-8FD0-6B9EB2D686B9Q34212422-472F0E08-B635-48B3-9BAB-834CBC457F15Q34540567-83CF4DFF-D659-43D3-A114-C24AFBA95E6FQ34576144-5BA2E6B6-7FAF-4E42-86F5-1BD2FE4278DAQ34758776-B077A2EB-D304-457E-A669-7E01AFB33052Q34777496-BB3D4E79-5CDD-434B-A726-16F78779397BQ35013240-36AF2BA1-0A17-40F7-9167-0142B2008FA3Q35029070-0289AA37-7464-4F3A-AF39-929B49EED713Q35065682-EADDE023-50D3-43D8-9B69-4CD4B7067B25Q35589979-5D0BB93B-EEAF-4A5D-85F9-5F53AC167551Q35688037-3A231D0E-1E7A-4507-8500-4DEEC7C623CCQ35690133-FDAB8171-843D-4AD4-A927-068C60EB2941Q35765748-337DFDD7-35D3-4E47-9295-9532D51C4276Q35850690-8263B039-E9FC-4334-9BEA-F62BF930F2F9Q35971342-865EB520-7BEA-4031-A659-B5442D776EF6Q36185520-376884BB-D010-4FF9-91BB-993EE4CB650DQ36236735-C21ED138-9990-4FF6-BCFC-0D7D294A3D90Q36259630-55F3B1AE-389C-4C78-8F56-DE8DDD1BAF0C
P2860
Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
Relationship between the appea ...... model of Parkinson's disease.
@en
Relationship between the appea ...... model of Parkinson's disease.
@nl
type
label
Relationship between the appea ...... model of Parkinson's disease.
@en
Relationship between the appea ...... model of Parkinson's disease.
@nl
prefLabel
Relationship between the appea ...... model of Parkinson's disease.
@en
Relationship between the appea ...... model of Parkinson's disease.
@nl
P2093
P1476
Relationship between the appea ...... e model of Parkinson's disease
@en
P2093
A R Crossman
J M Brotchie
P Ravenscroft
P304
P356
10.1523/JNEUROSCI.21-17-06853.2001
P407
P577
2001-09-01T00:00:00Z